کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2474753 | 1113161 | 2015 | 10 صفحه PDF | دانلود رایگان |

The objective of this study was to prepare cubosomal nanoparticles containing a hydrophilic anticancer drug 5-fluorouracil (5-FU) for liver targeting. Cubosomal dispersions were prepared by disrupting a cubic gel phase of monoolein and water in the presence of Poloxamer 407 as a stabilizer. Cubosomes loaded with 5-FU were characterized in vitro and in vivo. In vitro, 5-FU-loaded cubosomes entrapped 31.21% drug and revealed nanometer-sized particles with a narrow particle size distribution. In vitro 5-FU release from cubosomes exhibited a phase of rapid release of about half of the entrapped drug during the first hour, followed by a relatively slower drug release as compared to 5-FU solution. In vivo biodistribution experiments indicated that the cubosomal formulation significantly (P<0.05) increased 5-FU liver concentration, a value approximately 5-fold greater than that observed with a 5-FU solution. However, serum serological results and histopathological findings revealed greater hepatocellular damage in rats treated with cubosomal formulation. These results demonstrate the successful development of cubosomal nanoparticles containing 5-FU for liver targeting. However, further studies are required to evaluate hepatotoxicity and in vivo antitumor activity of lower doses of 5-FU cubosomal formulation in treatment of liver cancer.
5-Fluorouracil (5-FU) was successfully incorporated into cubosomal nanoparticles. Cubosomes loaded with 5-FU exhibited reasonable in vitro characteristics. Moreover, in vivo biodistribution of 5-FU in rat׳s liver indicated that the cubosomal formulation increased 5-FU liver concentration (nearly 5-fold) compared to 5-FU solution. In conclusion, cubosomes containing 5-FU has significant liver targeting properties.Figure optionsDownload as PowerPoint slide
Journal: Acta Pharmaceutica Sinica B - Volume 5, Issue 1, January 2015, Pages 79–88